Selank Dosage: Russian Clinical Use vs US Status
Last updated September 27, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← Selank encyclopedia entry · See also: Semax dosage · Regulatory tracker
Selank is a registered medicine in Russia (an anxiolytic developed at the Institute of Molecular Genetics) but has never been FDA-approved. In the US it circulates as an unregulated research chemical; it is in no category of FDA's 503A bulk-substance list (updated May 14, 2026), so pharmacies cannot compound it from bulk. The dosing below reflects Russian clinical and community practice, documented for education, not offered as instructions for US self-use.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
The short version
Selank is a synthetic analog of the immune-modulating peptide tuftsin, used intranasally and studied in Russia primarily as an anxiolytic — an anti-anxiety agent — that, unlike benzodiazepines, is reported not to cause sedation, dependence, or withdrawal. Like its sibling Semax, it is the rare peptide here with a real regulated history, just not in the US, so its dosing reads "approved there, unapproved here."
Intranasal dosing as reported
Russian clinical and community sources most commonly describe the following intranasal range. These are descriptive; US product is not the regulated Russian medicine.
Community-reported. Amounts users report, recorded for education. Not a recommendation, and not a dose any study has shown to be safe or effective.
| Parameter | Commonly reported |
|---|---|
| Amount | ~400–900 mcg per dose |
| Frequency | 2–3× daily |
| Route | Intranasal (drops/spray) |
| Form | Often a percentage solution |
A pattern often described in the nootropic community pairs Selank in the morning with Semax later in the day, on the rationale that one is calming and the other is activating. That is a community practice, not a validated combination protocol.
The US picture
The single most Selank-specific point is regulatory: it is a registered medicine in Russia but sits in no category of FDA's 503A bulk-substance list (updated May 14, 2026), so nothing sold in the US is the regulated product. Combined with the general problems of unregulated injectables and nasal solutions (unverified purity, dose, and sterility), that gap is the dominant safety consideration for US-sourced Selank. Selank's clinical record in Russia is described as clean, but that record was built on the regulated product, not on research-chemical vials. See the Regulatory Status Tracker.
Frequently asked questions
Is Selank addictive like a benzodiazepine?
Its reported advantage is that, in Russian clinical use, it does not produce the sedation, tolerance, or withdrawal associated with benzodiazepines — but that profile comes from the regulated product and supervised use.
Is it the same as Semax?
No; they are different peptides from the same Russian program, with Selank framed as anxiolytic and Semax as pro-cognitive. See the Semax dosage page.
Is it banned in sport?
Selank is not named on WADA's 2026 or 2027 Prohibited List, and because it is approved in Russia, whether S0 applies is unsettled: ask Global DRO before competing.
Sources
- Russian Federation drug registration (Selank); Institute of Molecular Genetics, Russian Academy of Sciences.
- Zozulia AA, et al. Selank in generalized anxiety disorder (Russian clinical study).
- U.S. FDA — Drugs@FDA database (no Selank approval); FDA's 503A bulk drug substance category list, updated May 14, 2026.
Medical disclaimer: Education only, not medical advice. Selank is not FDA approved; US-sourced product is unregulated. Dosing figures reflect Russian clinical/community practice, not a recommendation. Consult a licensed clinician.